Author name: MaryAnn

Mary Ann helps our editorial team keep readers informed by submitting relevant press releases from reputable sources like ACN Newswire. With a strong interest in business developments and media distribution, she supports our mission to deliver timely, accurate information to our audience.

Coya logo

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

– Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia Read Post »

News
Scroll to Top